Amlodipine/fimasartan

Drug Profile

Amlodipine/fimasartan

Alternative Names: BKC-002; Fimasartan/amlodipine

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Boryung Pharmaceutical
  • Class Antihypertensives; Dihydropyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Essential hypertension
  • Phase I Hypertension

Most Recent Events

  • 01 Jan 2017 Boryung Pharmaceutical completes a phase I trial in Hypertension (In volunteers) in South Korea (PO) (NCT02920047)
  • 31 Oct 2016 Phase-I clinical trials in Hypertension (In volunteers) in South Korea (PO) (NCT02920047)
  • 28 Sep 2016 Boryung Pharmaceutical plans a phase I bioequivalence trial in Healthy volunteers in South Korea (PO) (NCT02920047)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top